Objectives: Papillary renal cell carcinoma (pRCC) represents the largest subgroup of non-clear-cell kidney cancer. In this study, we assessed tumour characteristics and long-term prognosis of patients with pRCC in comparison with conventional clear-cell cancer (ccRCC).
Methods: We evaluated 744 patients who had undergone renal surgery for RCC between 1990 and 2005. The mean follow-up was 5.6 years, the patients being followed-up until December 2007.
Results: Both groups, pRCC and ccRCC, were alike concerning age, body mass index, and the incidence of regional lymph node or distant metastasis at diagnosis. The percentage of male patients was higher in pRCC than in ccRCC (73.8 vs. 60.3%, p = 0.006). Even though patients with pRCC presented more often with smaller (p = 0.039) and low-grade tumours (p = 0.006), there was no statistically significant difference in tumour recurrence or tumour related death. Kaplan-Meier curves revealed no differences regarding tumour specific survival between pRCC and ccRCC (p = 0.94; 5-year survival 78 vs. 77%).
Conclusions: Even though pRCC and ccRCC differ significantly in many aspects including histology and genetic alterations, their long term prognosis is comparable. As we could not confirm a favourable clinical course for pRCC in general, standardised aftercare programmes and-if necessary-systemic treatment, especially in the era of novel targeted drugs, are also needed for this common RCC subtype.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00432-008-0515-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and clinical significance of Claudin-3 expression in cancer: a tissue microarray study on 14,966 tumor samples.
Biomark Res
December 2024
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Background: Claudin-3 (CLDN3) participates in the formation of the tight-junctions (TJs) that regulate intercellular permeability. Altered CLDN3 expression has been linked to tumor progression in multiple tumor types. Despite its widespread expression in normal epithelial cells, CLDN3 is considered an attractive drug target candidate, since it may be more accessible in cancer cells than in normal cells due to their less orchestrated cell growth.
View Article and Find Full Text PDFEpidemiology and Treatment Outcomes of Renal Cell Carcinoma in Qassim Region, Saudi Arabia: A Retrospective Study.
Cureus
October 2024
Surgery, Unaizah Medical College, Qassim University, Buraydah, SAU.
Article Synopsis
- Renal cell carcinoma (RCC) is the most common type of kidney cancer, mainly affecting older males with comorbidities like diabetes and hypertension, and was studied in 73 patients at a hospital in Qassim, Saudi Arabia.
- The research showed that clear cell RCC is the most prevalent type, found in 60.3% of cases, and many tumors were moderately aggressive (Fuhrman grade 2), with 45.2% diagnosed incidentally.
- The primary treatment for RCC was surgical, predominantly laparoscopic, highlighting the need for better early diagnosis and screening strategies to manage the rising incidence of RCC in the region.
Niemann-Pick C1-like 1 as a Prognostic Marker in Renal Cell Carcinoma: A Retrospective Cohort Study.
Life (Basel)
November 2024
Family Medicine Clinic and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea.
Article Synopsis
- Renal cell carcinoma (RCC) is a severe kidney cancer with a poor prognosis, and the role of Niemann-Pick C1-Like 1 (NPC1L1) in its progression is not well understood.
- In this study, researchers compared NPC1L1 expression in normal versus RCC tissues and found that lower levels in RCC, especially in certain subtypes, were linked to worse patient survival.
- The findings indicate that higher NPC1L1 levels could be a potential independent prognostic marker for bad outcomes in RCC, necessitating further research on its mechanisms in cancer progression.
Evaluation of Renal Masses Using Contrast-Enhanced Ultrasound with Sonovue and Sonazoid.
Ultrasound Med Biol
January 2025
Department of Ultrasound, The Third Medical Center of Chinese PLA General Hospital, Beijing, China. Electronic address:
Objective: To explore the differences between SonoVue and Sonazoid contrast-enhanced ultrasound (CEUS) in evaluating enhancement features of renal masses and determine the diagnostic value of CEUS in clear cell renal cell carcinoma (ccRCC).
Methods: A total of 57 eligible patients were enrolled and divided into the ccRCC, papillary renal cell carcinoma (pRCC), non-ccRCC and non-pRCC malignancy groups, and benign mass groups based on their postsurgical histopathologic diagnosis. The enhancement features of renal masses following SonoVue and Sonazoid CEUS in each group were analyzed.
Is fat quantification based on proton density fat fraction useful for differentiating renal tumor types?
Abdom Radiol (NY)
September 2024
Dokuz Eylül University, Izmir, Turkey.
Article Synopsis
- This study evaluated the effectiveness of proton density fat fraction (PDFF) in diagnosing different types of renal tumors using a retrospective analysis of patient data over five years.
- A total of 226 patients with confirmed tumor types underwent multiparametric kidney MRI, measuring fat content in tumors and comparing it with histopathological results.
- Results indicated good diagnostic accuracy with notable differences in mean PDFF values across tumor types, highlighting the potential for PDFF in differentiating between renal tumors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!